The National Medical Products Administration in China approved Merck’s Keytruda as monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.
Keytruda is the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of patients with NSCLC.
